Teropavimab

DRUG4 trials

Sponsors

Gilead Sciences

Conditions

HIV InfectionsHIV-1 InfectionHIV-1-infection

Phase 1

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

CompletedNCT04811040

Gilead SciencesHIV-1 Infection

Start: 2021-04-08End: 2023-10-26Updated: 2025-01-27

Phase 2

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Active, not recruitingNCT05729568

Gilead SciencesHIV-1 Infection

Start: 2023-05-15End: 2030-12-01Updated: 2026-04-27

Phase 3

Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Not yet recruitingNCT07683000

Gilead SciencesHIV-1-infection

Start: 2026-07-01End: 2033-03-01Target: 590Updated: 2026-07-06

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Not yet recruitingNCT07682961

Gilead SciencesHIV Infections

Start: 2026-07-01End: 2033-03-01Target: 590Updated: 2026-07-06

Related Papers

Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab.

2026-01-01

P-1248. Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab

Open Forum Infectious Diseases2026-01-01

P-365. Pooled safety and tolerability of twice-yearly lenacapavir with teropavimab and zinlirvimab for HIV-1 treatment

Open Forum Infectious Diseases2026-01-01

Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab

The Journal of Infectious Diseases2025-03-304 citations

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.

2024-01-3031 citations